Analysis of efficacy of L-apigenin A in the treatment of Alzheimer's disease / 中国基层医药

ABSTRACT

Objective To evaluate the effects L-apigenin A on Alzheimer's disease(AD),and analyze the correlation between MMSE and ADAS-cog scores.Methods From January 2009 to December 2014,34 patients with AD were selected in Qinhuangdao Military Industry Hospital.They were treated with celery seed extract L-apigenin.The MMSE scores and ADAS-cog scores were evaluated before treatment and 18,36 and 72 d after treatment.The correlation between MMSE scores and ADAS-cog scores was analyzed.Results There were statistically significant differences in the MMSE scores between 72d after treatment [(22.59 ± 1.13)points] and before treatment [(20.53 ±1.42) points],18d after treatment [(20.44 ± 1.24) points] and 36d after treatment [(20.97 ± 1.17) points] (t =6.619,7.473,5.807,all P ＜ 0.05).There were statistically significant differences in ADAS-Cog scores between 72d after treatment[(17.09 ± 1.53) points] and before treatment [(20.47 ± 2.85) points],18d after treatment [(20.18 ± 2.34) points] and 36d after treatment [(20.18 ± 2.49) points] (t =6.093,6.445,6.165,all P ＜ 0.05).The MMSE score and ADAS-Cog score had negative correlation by Pearson analysis (r =-0.259,P =0.000).Conclusion L-apigenin A can significantly improve the cognitive function of patients with AD.There is significant negative correlation between the MMSE scores and ADAS-cog scores.